scholarly journals Gender differences in symptoms experienced by advanced cancer patients: a literature review

2013 ◽  
Vol 4 (2) ◽  
pp. 141
Author(s):  
Erin Wong ◽  
Gillian Bedard ◽  
Natalie Pulenzas ◽  
Breanne Lechner ◽  
Henry Lam ◽  
...  
Keyword(s):  
Gender Differences ◽  
Literature Review ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Sleep Problems ◽  
Gastrointestinal Symptoms ◽  
Advanced Cancer Patients ◽  
Retrospective Cohort Studies ◽  
And Gender ◽  
Multiple Symptoms

INTRODUCTION: Advanced cancer patients are multi-symptomatic and require attentive palliative care. As gender differences are apparent in multiple aspect of everyday life, this literature review aims to determine the gender differences seen in the population of advanced cancer patients and the symptoms that they experience. METHODS: A literature review was conducted using the OvidSP Medline database from 1946 to November 2012. Randomized, prospective or retrospective cohort studies on advanced cancer patients who were undergoing any type of palliative treatments (palliative radiation, chemotherapy) or those in which palliative treatments have failed (antalgic treatment) were included. The patient population, tools/questionnaire used and gender differences in symptoms found statistically or qualitatively significant in the respective studies were extracted. RESULTS: Of the 163 studies resulting from the literature search, nineteen publications were identified. Gender differences in multiple symptoms were discovered. Gender differences were commonly found in symptoms of emotional changes, fatigue, gastrointestinal symptoms (nausea, vomiting, and diarrhea) anxiety, tension, sleep problems and pain. CONCLUSION: At present, gender differences seen in the symptoms experienced by advanced cancer patients continues to be inconclusive. Further study investigating gender differences in the symptoms experienced by advanced cancer patients as the primary endpoint is recommended.

scholarly journals Gender differences in symptoms experienced by advanced cancer patients: a literature review

2013 ◽  
Vol 4 (2) ◽  
pp. 141-153 ◽  
Author(s):  
Erin Wong ◽  
Gillian Bedard ◽  
Natalie Pulenzas ◽  
Breanne Lechner ◽  
Henry Lam ◽  
...  
Keyword(s):  
Gender Differences ◽  
Literature Review ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Sleep Problems ◽  
Gastrointestinal Symptoms ◽  
Advanced Cancer Patients ◽  
Retrospective Cohort Studies ◽  
And Gender ◽  
Multiple Symptoms

INTRODUCTION: Advanced cancer patients are multi-symptomatic and require attentive palliative care. As gender differences are apparent in multiple aspect of everyday life, this literature review aims to determine the gender differences seen in the population of advanced cancer patients and the symptoms that they experience. METHODS: A literature review was conducted using the OvidSP Medline database from 1946 to November 2012. Randomized, prospective or retrospective cohort studies on advanced cancer patients who were undergoing any type of palliative treatments (palliative radiation, chemotherapy) or those in which palliative treatments have failed (antalgic treatment) were included. The patient population, tools/questionnaire used and gender differences in symptoms found statistically or qualitatively significant in the respective studies were extracted. RESULTS: Of the 163 studies resulting from the literature search, nineteen publications were identified. Gender differences in multiple symptoms were discovered. Gender differences were commonly found in symptoms of emotional changes, fatigue, gastrointestinal symptoms (nausea, vomiting, and diarrhea) anxiety, tension, sleep problems and pain. CONCLUSION: At present, gender differences seen in the symptoms experienced by advanced cancer patients continues to be inconclusive. Further study investigating gender differences in the symptoms experienced by advanced cancer patients as the primary endpoint is recommended.

Systematic literature review: xerostomia in advanced cancer patients

2014 ◽  
Vol 23 (3) ◽  
pp. 881-888 ◽  
Author(s):  
Sarika Hanchanale ◽  
Lucy Adkinson ◽  
Sunitha Daniel ◽  
Michelle Fleming ◽  
Stephen G Oxberry
Keyword(s):  
Literature Review ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Systematic Literature Review ◽  
Advanced Cancer Patients

Women know, and men wish they knew, prognostic information in advanced cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9037-9037
Author(s):  
Kalen M Fletcher ◽  
Holly Gwen Prigerson ◽  
Paul K Maciejewski
Keyword(s):  
Gender Differences ◽  
Life Expectancy ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Advanced Cancer Patients ◽  
Prognostic Information ◽  
Female Patients ◽  
Life Expectancy Estimate ◽  
Male Patients ◽  
Prospective Longitudinal

9037 Background: Little is known about gender differences in advanced cancer patient communication with oncologists. The few studies conducted have explored differences in preferences for prognostic disclosure. Our data allow us to test for gender differences in actual rates of audio-recorded, patient and oncologist reported, prognostic disclosures. We studied a group of advanced cancer patients to determine whether gender disparities exist in: a.) reported rates of prognostic disclosures from physicians and b.) willingness to estimate (versus not) one’s prognosis (i.e., amount of time left to live). Among patients who report never receiving a prognosis from their physician, we also tested for gender difference in wishing that this had been discussed. Methods: Coping with Cancer II is an NCI -funded multi-site, prospective longitudinal study of advanced cancer patients. Patients were interviewed after receiving scan results and asked if they have received a prognosis from their oncologist either at their most recent visit or at any time in the course of their disease. They are also asked if they would be willing to estimate their prognosis. Patients who state that they have not received a prognosis are asked if they wish that they had. Results: Among the advanced cancer patients studied (N=51; men=23, women=28), male cancer patients were significantly more likely to state never receiving a prognosis from their physician than female patients (OR=3.5; χ2=4.49, df=1, p=0.034). Male cancer patients were also significantly less willing to provide a life-expectancy estimate (OR=5.6; χ2=5.06, df=1, p=0.025). Among patients who stated never receiving a prognosis (N=27; men=16, women=11), male patients tended to be more likely than female patients to wish that their prognosis had been discussed (OR=7.8; χ2=3.11, df=1, p=0.078). Conclusions: Male advanced cancer patients are less likely than female cancer patients to state that they have received prognostic information and less willing to provide a life-expectancy estimate. Although male patients receive less open prognostic disclosure than female patients, male patients tend to be more likely than female patients to want prognostic information.

Effects of low molecular weight heparin on angiogenic factors in advanced cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21158-21158
Author(s):  
H. Coskun ◽  
N. Karakus ◽  
H. Vural ◽  
O. Akturk ◽  
G. Alanoglu
Keyword(s):  
Molecular Weight ◽  
Treatment Group ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Low Molecular Weight Heparin ◽  
Angiogenic Factors ◽  
Control Group ◽  
Low Molecular Weight ◽  
Advanced Cancer Patients ◽  
And Gender

21158 Background: The relationship between cancer and thrombosis is known for many years. Thrombosis can be associated with the biology and therapy of the disease in cancer patients. Low molecular weight heparin (LMWH) is shown to increase the duration of life in several types of cancer in clinical trials. Low molecular weight heparin is thought to be inhibiting with tumor growth and metastasis in several ways. In our study, we evaluate effects of LMWH therapy on angiogenic factors. Methods: Thirty-two advanced cancer patients who used prophylactic LMWH before chemotherapy. Median age was 64.5 years with range from 18 to 80. Sixteen healthy volunteers that are of same age and gender with study patients comprised the control group. VEGF, HGF, FGF, EGF, PDGF, ICAM, p-selectin, e-selectin levels were evaluated before and 7 days after LMWH therapy. Results: In baseline measurements HGF and ICAM levels were higher in treatment group compared the control group. But, levels of EGF and VEGF were not statistically significant higher in the treatment group compared to control group. After LMWH therapy, VEGF, FGF, PDGF, ICAM, e-selectin levels appeared to decrease and HGF, EGF, p-selectin levels appeared to increase but none of these changes were statistically significant. In a subset of seventeen patients with adenocarcinoma, levels of ICAM declined significantly after LMWH therapy this group. Before LMWH therapy; HGF was correlated with PDGF, VEGF, p-selectin, e-selectin; EGF was correlated with p-selectin; e-selectin was correlated with p- selectin. After therapy HGF was correlated with PDGF and EGF; PDGF was correlated with FGF and p-selectin; EGF was correlated with ICAM levels. Conclusions: In summary, with a short course of LMWH therapy a change in anjiogenic biomarkers was observed only in adenocarcinoma patients and this change was limited only to ICAM levels. The study focused on long term course was warranted. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document